Altimmune (NASDAQ:ALT) Stock Rating Lowered by Wall Street Zen

Altimmune (NASDAQ:ALT) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other research analysts have also recently issued reports on ALT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. B. Riley Financial cut their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Friday. Citizens Jmp reduced their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Barclays began coverage on shares of Altimmune in a research note on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price objective for the company. Finally, William Blair reiterated a “market perform” rating on shares of Altimmune in a research note on Thursday. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Altimmune currently has an average rating of “Hold” and a consensus price target of $16.60.

Altimmune Trading Up 0.9%

Shares of ALT stock opened at $3.54 on Friday. The company has a market capitalization of $399.42 million, a P/E ratio of -3.50 and a beta of 0.13. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. The business’s 50 day moving average is $4.48 and its two-hundred day moving average is $4.28. Altimmune has a twelve month low of $2.90 and a twelve month high of $7.73.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 54.03%. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.00 million. Equities analysts forecast that Altimmune will post -1.35 EPS for the current year.

Insider Activity at Altimmune

In other news, Director John Gill bought 12,500 shares of the business’s stock in a transaction on Tuesday, December 23rd. The stock was purchased at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the transaction, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,250. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jerome Benedict Durso purchased 12,500 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were purchased at an average cost of $4.13 per share, with a total value of $51,625.00. Following the completion of the purchase, the director owned 12,500 shares in the company, valued at $51,625. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 30,527 shares of company stock worth $125,278. 4.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALT. Arax Advisory Partners grew its stake in Altimmune by 99.7% during the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after acquiring an additional 4,076 shares in the last quarter. SBI Securities Co. Ltd. lifted its position in shares of Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after purchasing an additional 1,928 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in Altimmune in the 1st quarter worth about $50,000. Victory Capital Management Inc. acquired a new position in Altimmune in the 3rd quarter worth about $38,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Altimmune by 108.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after purchasing an additional 5,253 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune News Roundup

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Company advanced pemvidutide development — management reiterated plans to initiate a Phase 3 MASH trial in 2026, pemvidutide received FDA Breakthrough Therapy designation for MASH, and RECLAIM Phase 2 topline data in AUD is expected in 3Q 2026. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Balance sheet strengthened — company reported about $274M in cash, cash equivalents and short-term investments at year-end and completed a $75M registered direct offering in January, supporting clinical programs and runway. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Company outlined a large, 1,800‑patient Phase III MASH design and signaled cash runway into 2028 as pemvidutide advances — this reduces near-term execution risk for the lead program. Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028
• Neutral Sentiment: B. Riley cut its price target from $18 to $13 but kept a Buy rating — the new target still implies meaningful upside vs. current levels, though it reduces analyst enthusiasm relative to prior coverage. Benzinga
• Neutral Sentiment: Earnings call and transcripts are available for review — useful for investors who want management’s commentary on timelines, trial designs and cash runway. Altimmune Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Reported short-interest notes appear to show anomalous/zero values in public data feeds and are not a reliable signal at this time.
• Negative Sentiment: Q4 earnings missed estimates — EPS of ($0.27) vs. consensus ($0.25) and immaterial GAAP revenue ($0.03M); very large negative margins and negative ROE highlight ongoing R&D spending and lack of commercial revenue. Altimmune stock edges down on fourth quarter earnings miss

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.